Medical Physics Seminar

The number of preclinical and clinical drug candidates for Alzheimer’s disease (AD) is dwarfed by cancer drugs at similar stages, by a factor of 100. One important contributor for this dire situation is the lack of reliable, low-cost, and efficient tools to assess treatment endpoints and disease progression in AD models.